Pyxis Oncology is a biotechnology firm that develops antibody therapeutics intended to promote the body's immune response to cancer.
Pyxis Oncology has raised $50.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in June 2026.
Pyxis Oncology's investors include RA Capital Management, Janus Henderson Investors, RTW Investments, Perceptive Advisors, Blue Owl.
Pyxis Oncology is headquartered in Boston, United States.
Pyxis Oncology is a biotechnology firm that develops antibody therapeutics intended to promote the body's immune response to cancer.
Pyxis Oncology is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Pyxis Oncology — Funding & Investors." VCBacked, June 30, 2026, https://www.vcbacked.co/company/pyxis-oncology. Accessed September 29, 2026.
VCBacked. (2026). Pyxis Oncology — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/pyxis-oncology
{{cite web |title=Pyxis Oncology — Funding & Investors |url=https://www.vcbacked.co/company/pyxis-oncology |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated